RxDoctor Payments Data

Harshinie Amaratunge, MD

Gastroenterology · Houston, TXNPI 1265696504

Payments from drug & device makers

$14,105in general payments, 2019–2025

Across 700 payments — averaging $20.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Johnson & Johnson$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$836
  • QOL Medical, LLC$570
  • Sanofi$508
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$14,052100%
  • Education$360%
  • Entertainment$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$14,105 in reported general payments places this provider in the 75th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$214,920
Medicare patients
360
Services billed
6,187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase45$151,420
LinzessLinaclotide56$57,689
XifaxanRifaximin14$27,716
TrulancePlecanatide23$21,731
Mesalamine41$13,822
MovantikNaloxegol Oxalate13$8,517
Sucralfate19$6,435
Dexlansoprazole DrDexlansoprazole25$5,837
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C40$5,329
ClenpiqSod Picosulf/Mag Ox/Citric Ac24$4,004
Omeprazole196$2,474
Pantoprazole Sodium158$2,456
Esomeprazole Magnesium26$1,133
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates17$1,035
Famotidine105$863

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$4,709$209,109101 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu$836$54,77577 claims
Redhill Biopharma Inc.Movantik$125$8,51713 claims
Ferring Pharmaceuticals Inc.Clenpiq$98$4,00424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →